3IS9 image
Deposition Date 2009-08-25
Release Date 2010-04-07
Last Version Date 2023-09-06
Entry Detail
PDB ID:
3IS9
Title:
Crystal structure of the HIV-1 reverse transcriptase (RT) in complex with the alkenyldiarylmethane (ADAM) Non-nucleoside RT Inhibitor dimethyl 3,3'-(6-methoxy-6-oxohex-1-ene-1,1-diyl)bis(5-cyano-6-methoxybenzoate).
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
2.55 Å
R-Value Free:
0.28
R-Value Work:
0.25
R-Value Observed:
0.25
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Reverse transcriptase/ribonuclease H
Gene (Uniprot):gag-pol
Mutations:C879S, K771A, K772A
Chain IDs:A
Chain Length:558
Number of Molecules:1
Biological Source:Human immunodeficiency virus type 1 BH10
Polymer Type:polypeptide(L)
Molecule:Reverse transcriptase
Gene (Uniprot):gag-pol
Mutations:C879S
Chain IDs:B
Chain Length:428
Number of Molecules:1
Biological Source:Human immunodeficiency virus type 1 BH10
Ligand Molecules
Primary Citation
Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.
J.Med.Chem. 52 6467 6473 (2009)
PMID: 19775161 DOI: 10.1021/jm901167t

Abstact

Two crystal structures have been solved for separate complexes of alkenyldiarylmethane (ADAM) nonnucleoside reverse transcriptase inhibitors (NNRTI) 3 and 4 with HIV-1 reverse transcriptase (RT). The structures reveal inhibitor binding is exclusively hydrophobic in nature and the shape of the inhibitor-bound NNRTI binding pocket is unique among other reported inhibitor-RT crystal structures. Primarily, ADAMs 3 and 4 protrude from a large gap in the back side of the binding pocket, placing portions of the inhibitors unusually close to the polymerase active site and allowing 3 to form a weak hydrogen bond with Lys223. The lack of additional stabilizing interactions, beyond the observed hydrophobic surface contacts, between 4 and RT is quite perplexing given the extreme potency of the compound (IC(50) </= 1 nM). ADAM 4 was designed to be hydrolytically stable in blood plasma, and an investigation of its hydrolysis in rat plasma demonstrated it has a significantly prolonged half-life in comparison to ADAM lead compounds 1 and 2.

Legend

Protein

Chemical

Disease

Primary Citation of related structures